Single- and repeated-dose @entity137 study of bevacizumab, ranibizumab, and aflibercept in XXXX cells under normal and oxidative stress conditions.

@entity1 @entity1603 @entity5568 @entity137 @entity522 @entity7 @entity98 @entity989
UNASSIGNED: We assessed the effect of single and repeated doses of bevacizumab, ranibizumab, and aflibercept on cell viability, proliferation, permeability, and apoptosis of @entity1 cells. @entity98 and @entity1603 assays were used to determine viability and proliferation after single or repeated doses of anti- @entity7 drugs under normal and oxidative stress conditions. @entity522 expression after single and repeated doses of the 3 drugs was assessed using immunofluorescence. Transepithelial-electrical-resistance (TER) was measured to study the effect of anti-VEGFs on @entity989 ( @entity989 ) permeability under normal and oxidative stress conditions. Flow cytometry was used to detect intracellular accumulation of the drugs. Finally, a wound healing assay was performed to investigate the effect of the drugs on @entity989 cell migration. Single and multiple doses of anti- @entity7 drugs had no effect on cell viability and proliferation. The oxidative effect of @entity5568 decreased cell viability and proliferation; however, no difference was observed between anti- @entity7 treatments. Immunofluorescence performed after single and repeated doses of the drugs revealed some @entity522 expression. Interestingly, anti-VEGFs restored the increased permeability induced by @entity5568 . The 3 drugs accumulated inside the cells and were detectable 5days after treatment. Finally, none of the drugs affected migration. In conclusion, no measureable @entity137 effect was observed after single or repeated doses of @entity7 antagonists under normal and oxidative stress. Intracellular accumulation of the drugs does not seem to be @entity137 or affect cell functions. Our study suggests that anti-VEGFs could have a preventive effect on the maintenance of the @entity989 barrier under oxidative stress.
